Improving patient outcomes is at the heart of T2 Biosystems’ mission. Studies have demonstrated that faster targeted therapy for sepsis patients saves lives – cutting the mortality rate in half.1
Today, empiric therapy misses 40% of sepsis patients.2 T2Direct Diagnostics™ provide faster species identification of many of the most common and deadly sepsis-causing pathogens, allowing earlier targeted therapy. Earlier targeted therapy for these pathogens may prevent may prevent a bloodstream infection from progressing to sepsis. In addition, the ability to quickly rule-out clinically important pathogens can positively impact patient management.
A study published in Future Microbiology, found that the T2Candida Panel could potentially lead to a reduction of 60.6% Candida-related deaths per hospital.3
T2Direct Diagnostics – Proven to Deliver Improved Patient Outcomes
- Henry Ford Health System in Michigan reduced the median ICU length of stay per patient by 7 days and showed a trend in reducing total length of stay (LOS) by an average of 4 days per patient.4 In addition, 75% of negative patients had antifungals discontinued or de-escalated.
- Lee Health System in Florida experienced a reduction in length of stay (LOS) by an average of 7 days.5
- At Huntsville Hospital in Alabama, approximately two-thirds of patients with negative T2 results experienced reduced antifungal therapy – and negative results decreased the use of micafungin by more than 2 days.
Watch the Henry Ford Health System webinar on implementation and patient outcomes.
Request a T2Direct Diagnostics meeting.